Corticosteroid switch after progression on abiraterone acetate plus prednisone
- 35 Downloads
Abiraterone acetate plus prednisone is approved in metastatic castration-resistant prostate cancer. There is some evidence in favour of the steroid switch from prednisone to dexamethasone in patients who progressed whilst on abiraterone acetate plus prednisone or prednisolone.
Materials and Methods
The aim of this review is to discuss the results from the clinical studies available, examining potential mechanisms of action and patient selection criteria for this treatment option.
A total of four studies were evaluated. Among possible eligibility criteria for steroid switch, we found: PSA progression without any radiological or clinical progression during abiraterone acetate + prednisone; no high-grade adverse events related to CYP-17 inhibition; and unfitness for chemotherapy or radium-223.
Although large randomized prospective trials are warranted, steroid switch seems to offer a good option for certain patients treated with abiraterone acetate plus prednisone or prednisolone.
KeywordsDexamethasone Prednisone Abiraterone Switch
Compliance with ethical standards
Conflict of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.
- 7.Fizazi K, Scher HI, Molina A et al (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13(10):983–992. (Erratum in: Lancet Oncol. 2012 Nov;13(11):e464. Lancet Oncol. 2014 Aug;15(9):e365)CrossRefGoogle Scholar
- 8.Ryan CJ, Smith MR, Fizazi K et al (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16(2):152–160.CrossRefGoogle Scholar
- 11.Khandwala HM, Vassilopoulou-Sellin R, Logethetis CJ et al (2001) Corticosteroid-induced inhibition of adrenal androgen production in selected patients with prostate cancer. Endocr Pract 7:11–15Google Scholar
- 12.Crona DJ, Whang YE (2017) Androgen receptor‑dependent and independent mechanisms involved in prostate cancer therapy resistance. Cancers (Basel) 9: pii: E67Google Scholar
- 19.Richards J, Lim AC, Hay CW et al (2012) Interactions of abiraterone, eplerenone, and prednisolone with wild‑type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res 72: 2176‑2182Google Scholar
- 29.Fenioux C, Louvet C, Charton E et al (2018) Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer. BJU IntGoogle Scholar
- 30.Romero-Laorden N, Lozano R, Jayaram A et al (2018) Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study). Br J CancerGoogle Scholar
- 31.Roviello G, Petrioli R, Bonetta A et al (2018) Corticosteroid switch in heavily pre-treated castration-resistant prostate cancer patients progressed on abiraterone acetate plus prednisone. Invest New Drugs 2018Google Scholar